Condition: Chronic Neuropathic Pain · Sponsor: Sangamo Therapeutics
This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN). ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due to small fiber neuropathy (SFN).
This description comes directly from the study's public registry record.
Patient Advocacy · 510-307-7266 · clinicaltrials@sangamo.com
Always discuss trial participation with your own doctor first.
| HonorHealth | Scottsdale, Arizona, United States | Recruiting |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | Recruiting |
| The University of California, San Diego | La Jolla, California, United States | Not Yet Recruiting |
| Johns Hopkins University | Baltimore, Maryland, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Dartmouth Hitchcock Medical Center | Lebanon, New Hampshire, United States | Not Yet Recruiting |
| Columbia University Irving Medical Center (CUIMC) and New York-Presbyterian Hospital (NYPH) | New York, New York, United States | Recruiting |
| University of North Carolina Medical Center | Chapel Hill, North Carolina, United States | Not Yet Recruiting |
| Vanderbilt University | Nashville, Tennessee, United States | Not Yet Recruiting |
| University of Utah | Salt Lake City, Utah, United States | Not Yet Recruiting |
| Virginia Commonwealth University | Richmond, Virginia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06980948